NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
Clinical Trials
15 trialsNCT03598270 2024-08-30
ANITA
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Completed
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT00129389 2023-03-07
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT01379989 2022-02-09
INOVATYON
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT02903004 2021-08-25
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Completed
NCT02631876 2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3 Completed
NCT02421588 2020-04-03
CORAIL
PharmaMar
Phase 3 Completed
NCT01935492 2020-01-18
Stop&Go
Borstkanker Onderzoek Groep
Phase 3 Completed
NCT01846611 2019-04-01
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development, LLC
Phase 3 Completed
NCT00097981 2017-04-07
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00103506 2015-10-19
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT00113607 2014-06-27
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00091442 2014-04-21
A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00191607 2007-01-26
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
Eli Lilly and Company
Phase 3 Completed